Clik here to view.
Axcelead Drug Discovery Partners とERS Genomics、CRISPR /...
藤沢市 （ビジネスワイヤ）– Axcelead Drug Discovery Partners 株式会社社（代表取締役社長：池浦義典、本社：神奈川県藤沢市、以下「アクセリード」）とERS Genomics Limited（代表取締役社長：エリック・ローズ、本社：アイルランド ダブリン、以下「ERS」）は、ERSが管理するCRISPR /...
View ArticleClik here to view.
Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9...
FUJISAWA, Japan & DUBLIN Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a...
View ArticleClik here to view.
メダクタインターナショナルがFrancesco Siccardiを次期最高経営責任者に任命
スイス・カステルサンピエトロ （ビジネスワイヤ） — 革新的な人工関節置換術／脊椎手術関連製品の設計で世界をリードする家族所有の非上場企業メダクタインターナショナルは本日、著名な生物医学工学者でメダクタインターナショナルの現エグゼクティブバイスプレジデントのFrancesco...
View ArticleClik here to view.
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A Without...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Hemlibra®...
View ArticleClik here to view.
Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential...
MELBOURNE, Australia & SAN FRANCISCO Prana Biotechnology Ltd (ASX: PBT) (NASDAQ: PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the International...
View ArticleClik here to view.
Valneva Receives FDA Approval for Accelerated Vaccine Dosing Schedule for...
GAITHERSBURG, Md. Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced U.S. Food and Drug Administration (FDA) approval of an accelerated dosing regimen for...
View ArticleClik here to view.
シアトル・ジェネティクスと武田薬品がCD30発現末梢性T細胞リンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を評価する第3相ECH...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Clik here to view.
武田确定临时股东大会登记日期
日本大阪 (美国商业资讯)–在于2018年5月8日宣布建议收购Shire plc (Shire)之后，武田药品工业株式会社(TSE: 4502)（“武田”或“公司”）今天宣布公司已确定临时股东大会登记日期，就与拟议收购有关的以下必要事项进行投票。 关于临时股东大会的登记日期...
View ArticleClik here to view.
Visioneering Technologies, Inc. Enters European Market
ATLANTA Visioneering Technologies, Inc. (ASX: VTI), an innovative US-based medical device company dedicated to developing advanced products that improve vision, today announced that Medilens Nordic...
View ArticleClik here to view.
Clik here to view.
GenAhead Bio and ERS Genomics Enter into CRISPR/Cas9 License Agreement
FUJISAWA CITY, Japan & DUBLIN GenAhead Bio Incorporated (“GenAhead”) and ERS Genomics Limited (“ERS Genomics”) announced today a non-exclusive license agreement to provide GenAhead with access...
View ArticleClik here to view.
GenAhead Bio：ERS GenomicsとCRISPR / Cas9技術基本特許における非独占的ライセンス契約を締結
藤沢市 (美國商業資訊)–GenAhead Bio Incorporated（以下「GenAhead」）とERS Genomics Limited（以下「ERS Genomics」）は、GenAheadにERS Genomicが管理するCRISPR /...
View ArticleClik here to view.
PharmAbcine宣布FDA受理TTAC-0001用于治疗复发胶质母细胞瘤的IND申请
韩国大田 (美国商业资讯) — PharmAbcine, Inc是一家临床阶段生物技术公司，开发新型抗体治疗药物，用于多种癌症适应证，该公司宣布已收到美国食品药品管理局(FDA)针对其旗舰抗体TTAC-0001在研新药(“IND”)申请而签发的“可开展研究通知书”。该通知书允许公司开始启动美国临床试验单位开展贝伐珠单抗(Avastin®)难治复发GBM患者II期临床试验。...
View ArticleClik here to view.
Seattle Genetics与武田发布ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — Seattle Genetics, Inc. (Nasdaq:SGEN)与武田药品工业株式会社(TSE:4502)今天宣布，3期ECHELON-2临床试验达到主要终点。该试验显示，ADCETRIS (brentuximab...
View ArticleClik here to view.
Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company...
BEIJING Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), became aware Monday October 8, 2018 that unauthorized changes have been made to the Hong Kong Companies Registry for Sinovac...
View ArticleClik here to view.
WellSky and Digi-Trax Partner to Power Safer and More Efficient Cellular...
LENEXA, Kan. WellSky, a leading health and community care technology company backed by TPG Capital, and Digi-Trax Corporation, a global leader in compliance labeling solutions, have formed an...
View ArticleClik here to view.
Evecxia Licenses Additional IP from NUS, NUH and NTU in Singapore
RESEARCH TRIANGLE PARK, N.C. Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, today announced that it has licensed exclusive, world-wide rights to develop and...
View ArticleClik here to view.
德累斯顿心脏中心成为Imricor的首家商业化临床单位
明尼阿波利斯 (美国商业资讯) — Imricor今天宣布，该公司与德国德累斯顿心脏中心签署Advantage-MR EP记录仪/刺激仪系统并支持Vision-MR器械1的首份商业化合同。该协议将德累斯顿心脏中心置于MRI引导心脏消融临床进展的前沿，使该医院成为成长中的介入心脏磁共振(iCMR)领域的全球领导者。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Sale of Its API Manufacturing Business...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a...
View Article